Categories: Wire Stories

JSR Life Sciences� Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy

Launch marks product�s first use in a commercial therapeutic

SUNNYVALE, Calif.–(BUSINESS WIRE)–JSR Life Sciences, LLC today announced that its lead product, Amsphere™ A3, has been incorporated for the first time into the commercial manufacturing of an FDA-approved treatment.

Amsphere™ A3 is a next generation Protein-A chromatography resin that enables advanced protein separation in downstream processing of therapeutic antibodies. Since its launch in January 2016, the product has seen rapid adoption as an alternative option for downstream purification in biologics processing.

“The support provided by our global applications teams really helped make this happen,” said Hideaki Nomura, general manager of JSR Life Sciences’ Bioprocess Division. “Despite international supply chain disruptions affecting most global companies, we are in a position not only to maintain our commitments, but to expand our bioprocess purification materials to support more biologics companies in their pursuit of promising treatments for patients.”

The company is currently expanding on all fronts to facilitate increased manufacturing of biologics. Along with its first commercial launch, Amsphere™ A3 is currently being used in more than 95 clinical programs worldwide.

About JSR Life Sciences, LLC

A business unit of JSR Corporation, JSR Life Sciences, LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR Life Sciences provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR Life Sciences offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR Life Sciences’ global network of affiliates includes Crown Bioscience Inc., KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com.

Contacts

Missy Bindseil

JSR Life Sciences Company Inquiries

Director, Marketing & Communications

mbindseil@jsr-nahq.com

Mike Beyer

JSR Life Sciences Media Inquiries

Sam Brown Inc.

mikebeyer@sambrown.com
+1 312-961-2502

Alex

Recent Posts

TVB ESG Awards 2025 Presentation Ceremony

Hong Kong and Macau Organisations Honoured for Outstanding Achievements ESG-led Business for a Sustainable FutureHONG…

13 hours ago

2025 Annual Claims Data Report: Bridging Information Gaps with Full Disclosure

HONG KONG SAR - Media OutReach Newswire -19 December 2025 - HKAccidentLawyers.com and the HKCivilClaim.com…

14 hours ago

Vingroup Simultaneously Launches and Inaugurates 11 Key Projects in Vietnam

HANOI, VIETNAM - Media OutReach Newswire – 19 December 2025 - In celebration of the…

14 hours ago

Yes Unboxes the Drama with 5g advanced Broadband + FREE 1 Year iQIYI Access

Get ready, Malaysia! Plug & Play 5g advanced home WiFi with premium streaming has now…

16 hours ago

Vinfast Honored in Indonesia with Kumparan Awards: Impact Makers 2025

JAKARTA, INDONESIA - Media OutReach Newswire – 19 December 2025 – At the Kumparan Awards:…

16 hours ago

SIM Strengthens Graduate Employability Through Structured Internship Pathways

SINGAPORE - Media OutReach Newswire - 19 December 2025 – As hiring expectations continue to…

17 hours ago